The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Cancer Gene Therapy-Global Market Insights and Sales Trends 2024
Synopsis
Cancer could be defined as uncontrolled cell growth in the body leading to organ malfunction. If untreated, it can lead to death. Uncontrolled growth of cell is managed by the body in several ways, one of them is by deploying white blood cells to detect and eradicate these cancerous cells. It has been discovered that the immune system could be manipulated to influence cancerous cells to destroy itself.
The global Cancer Gene Therapy market size is expected to reach US$ 1657.7 million by 2029, growing at a CAGR of 17.8% from 2023 to 2029. The market is mainly driven by the significant applications of Cancer Gene Therapy in various end use industries. The expanding demands from the Hospitals, Diagnostics Centers and Research Institutes,, are propelling Cancer Gene Therapy market. Oncolytic Virotherapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Gene Transfer segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Cancer Gene Therapy, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Cancer Gene Therapy market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Cancer Gene Therapy market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Cancer Gene Therapy sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Cancer Gene Therapy covered in this report include Adaptimmune, Bluebird bio, Celgene, Shanghai Sunway Biotech, Shenzhen SiBiono GeneTech, SynerGene Therapeutics, Altor BioScience, Amgen and Argenx, etc.
The global Cancer Gene Therapy market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Adaptimmune
Bluebird bio
Celgene
Shanghai Sunway Biotech
Shenzhen SiBiono GeneTech
SynerGene Therapeutics
Altor BioScience
Amgen
Argenx
BioCancell
GlaxoSmithKline
Merck
OncoGenex Pharmaceuticals
Transgene
Global Cancer Gene Therapy market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Cancer Gene Therapy market, Segment by Type:
Oncolytic Virotherapy
Gene Transfer
Gene-Induced Immunotherapy
Global Cancer Gene Therapy market, by Application
Hospitals
Diagnostics Centers
Research Institutes
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Cancer Gene Therapy companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Cancer could be defined as uncontrolled cell growth in the body leading to organ malfunction. If untreated, it can lead to death. Uncontrolled growth of cell is managed by the body in several ways, one of them is by deploying white blood cells to detect and eradicate these cancerous cells. It has been discovered that the immune system could be manipulated to influence cancerous cells to destroy itself.
The global Cancer Gene Therapy market size is expected to reach US$ 1657.7 million by 2029, growing at a CAGR of 17.8% from 2023 to 2029. The market is mainly driven by the significant applications of Cancer Gene Therapy in various end use industries. The expanding demands from the Hospitals, Diagnostics Centers and Research Institutes,, are propelling Cancer Gene Therapy market. Oncolytic Virotherapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Gene Transfer segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Cancer Gene Therapy, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Cancer Gene Therapy market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Cancer Gene Therapy market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Cancer Gene Therapy sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Cancer Gene Therapy covered in this report include Adaptimmune, Bluebird bio, Celgene, Shanghai Sunway Biotech, Shenzhen SiBiono GeneTech, SynerGene Therapeutics, Altor BioScience, Amgen and Argenx, etc.
The global Cancer Gene Therapy market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Adaptimmune
Bluebird bio
Celgene
Shanghai Sunway Biotech
Shenzhen SiBiono GeneTech
SynerGene Therapeutics
Altor BioScience
Amgen
Argenx
BioCancell
GlaxoSmithKline
Merck
OncoGenex Pharmaceuticals
Transgene
Global Cancer Gene Therapy market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Cancer Gene Therapy market, Segment by Type:
Oncolytic Virotherapy
Gene Transfer
Gene-Induced Immunotherapy
Global Cancer Gene Therapy market, by Application
Hospitals
Diagnostics Centers
Research Institutes
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Cancer Gene Therapy companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Cancer Gene Therapy
1.1 Cancer Gene Therapy Market Overview
1.1.1 Cancer Gene Therapy Product Scope
1.1.2 Cancer Gene Therapy Market Status and Outlook
1.2 Global Cancer Gene Therapy Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Cancer Gene Therapy Market Size by Region (2018-2029)
1.4 Global Cancer Gene Therapy Historic Market Size by Region (2018-2023)
1.5 Global Cancer Gene Therapy Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Cancer Gene Therapy Market Size (2018-2029)
1.6.1 North America Cancer Gene Therapy Market Size (2018-2029)
1.6.2 Europe Cancer Gene Therapy Market Size (2018-2029)
1.6.3 Asia-Pacific Cancer Gene Therapy Market Size (2018-2029)
1.6.4 Latin America Cancer Gene Therapy Market Size (2018-2029)
1.6.5 Middle East & Africa Cancer Gene Therapy Market Size (2018-2029)
2 Cancer Gene Therapy Market by Type
2.1 Introduction
2.1.1 Oncolytic Virotherapy
2.1.2 Gene Transfer
2.1.3 Gene-Induced Immunotherapy
2.2 Global Cancer Gene Therapy Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Cancer Gene Therapy Historic Market Size by Type (2018-2023)
2.2.2 Global Cancer Gene Therapy Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Cancer Gene Therapy Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Cancer Gene Therapy Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Cancer Gene Therapy Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Cancer Gene Therapy Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Cancer Gene Therapy Revenue Breakdown by Type (2018-2029)
3 Cancer Gene Therapy Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Diagnostics Centers
3.1.3 Research Institutes
3.2 Global Cancer Gene Therapy Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Cancer Gene Therapy Historic Market Size by Application (2018-2023)
3.2.2 Global Cancer Gene Therapy Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Cancer Gene Therapy Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Cancer Gene Therapy Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Cancer Gene Therapy Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Cancer Gene Therapy Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Cancer Gene Therapy Revenue Breakdown by Application (2018-2029)
4 Cancer Gene Therapy Competition Analysis by Players
4.1 Global Cancer Gene Therapy Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Cancer Gene Therapy as of 2022)
4.3 Date of Key Players Enter into Cancer Gene Therapy Market
4.4 Global Top Players Cancer Gene Therapy Headquarters and Area Served
4.5 Key Players Cancer Gene Therapy Product Solution and Service
4.6 Competitive Status
4.6.1 Cancer Gene Therapy Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Adaptimmune
5.1.1 Adaptimmune Profile
5.1.2 Adaptimmune Main Business
5.1.3 Adaptimmune Cancer Gene Therapy Products, Services and Solutions
5.1.4 Adaptimmune Cancer Gene Therapy Revenue (US$ Million) & (2018-2023)
5.1.5 Adaptimmune Recent Developments
5.2 Bluebird bio
5.2.1 Bluebird bio Profile
5.2.2 Bluebird bio Main Business
5.2.3 Bluebird bio Cancer Gene Therapy Products, Services and Solutions
5.2.4 Bluebird bio Cancer Gene Therapy Revenue (US$ Million) & (2018-2023)
5.2.5 Bluebird bio Recent Developments
5.3 Celgene
5.3.1 Celgene Profile
5.3.2 Celgene Main Business
5.3.3 Celgene Cancer Gene Therapy Products, Services and Solutions
5.3.4 Celgene Cancer Gene Therapy Revenue (US$ Million) & (2018-2023)
5.3.5 Shanghai Sunway Biotech Recent Developments
5.4 Shanghai Sunway Biotech
5.4.1 Shanghai Sunway Biotech Profile
5.4.2 Shanghai Sunway Biotech Main Business
5.4.3 Shanghai Sunway Biotech Cancer Gene Therapy Products, Services and Solutions
5.4.4 Shanghai Sunway Biotech Cancer Gene Therapy Revenue (US$ Million) & (2018-2023)
5.4.5 Shanghai Sunway Biotech Recent Developments
5.5 Shenzhen SiBiono GeneTech
5.5.1 Shenzhen SiBiono GeneTech Profile
5.5.2 Shenzhen SiBiono GeneTech Main Business
5.5.3 Shenzhen SiBiono GeneTech Cancer Gene Therapy Products, Services and Solutions
5.5.4 Shenzhen SiBiono GeneTech Cancer Gene Therapy Revenue (US$ Million) & (2018-2023)
5.5.5 Shenzhen SiBiono GeneTech Recent Developments
5.6 SynerGene Therapeutics
5.6.1 SynerGene Therapeutics Profile
5.6.2 SynerGene Therapeutics Main Business
5.6.3 SynerGene Therapeutics Cancer Gene Therapy Products, Services and Solutions
5.6.4 SynerGene Therapeutics Cancer Gene Therapy Revenue (US$ Million) & (2018-2023)
5.6.5 SynerGene Therapeutics Recent Developments
5.7 Altor BioScience
5.7.1 Altor BioScience Profile
5.7.2 Altor BioScience Main Business
5.7.3 Altor BioScience Cancer Gene Therapy Products, Services and Solutions
5.7.4 Altor BioScience Cancer Gene Therapy Revenue (US$ Million) & (2018-2023)
5.7.5 Altor BioScience Recent Developments
5.8 Amgen
5.8.1 Amgen Profile
5.8.2 Amgen Main Business
5.8.3 Amgen Cancer Gene Therapy Products, Services and Solutions
5.8.4 Amgen Cancer Gene Therapy Revenue (US$ Million) & (2018-2023)
5.8.5 Amgen Recent Developments
5.9 Argenx
5.9.1 Argenx Profile
5.9.2 Argenx Main Business
5.9.3 Argenx Cancer Gene Therapy Products, Services and Solutions
5.9.4 Argenx Cancer Gene Therapy Revenue (US$ Million) & (2018-2023)
5.9.5 Argenx Recent Developments
5.10 BioCancell
5.10.1 BioCancell Profile
5.10.2 BioCancell Main Business
5.10.3 BioCancell Cancer Gene Therapy Products, Services and Solutions
5.10.4 BioCancell Cancer Gene Therapy Revenue (US$ Million) & (2018-2023)
5.10.5 BioCancell Recent Developments
5.11 GlaxoSmithKline
5.11.1 GlaxoSmithKline Profile
5.11.2 GlaxoSmithKline Main Business
5.11.3 GlaxoSmithKline Cancer Gene Therapy Products, Services and Solutions
5.11.4 GlaxoSmithKline Cancer Gene Therapy Revenue (US$ Million) & (2018-2023)
5.11.5 GlaxoSmithKline Recent Developments
5.12 Merck
5.12.1 Merck Profile
5.12.2 Merck Main Business
5.12.3 Merck Cancer Gene Therapy Products, Services and Solutions
5.12.4 Merck Cancer Gene Therapy Revenue (US$ Million) & (2018-2023)
5.12.5 Merck Recent Developments
5.13 OncoGenex Pharmaceuticals
5.13.1 OncoGenex Pharmaceuticals Profile
5.13.2 OncoGenex Pharmaceuticals Main Business
5.13.3 OncoGenex Pharmaceuticals Cancer Gene Therapy Products, Services and Solutions
5.13.4 OncoGenex Pharmaceuticals Cancer Gene Therapy Revenue (US$ Million) & (2018-2023)
5.13.5 OncoGenex Pharmaceuticals Recent Developments
5.14 Transgene
5.14.1 Transgene Profile
5.14.2 Transgene Main Business
5.14.3 Transgene Cancer Gene Therapy Products, Services and Solutions
5.14.4 Transgene Cancer Gene Therapy Revenue (US$ Million) & (2018-2023)
5.14.5 Transgene Recent Developments
6 North America
6.1 North America Cancer Gene Therapy Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Cancer Gene Therapy Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Cancer Gene Therapy Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Cancer Gene Therapy Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Cancer Gene Therapy Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Cancer Gene Therapy Market Dynamics
11.1 Cancer Gene Therapy Industry Trends
11.2 Cancer Gene Therapy Market Drivers
11.3 Cancer Gene Therapy Market Challenges
11.4 Cancer Gene Therapy Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
